US health authorities will allow emergency use of Gilead's coronavirus treatment
- The US Food and Drug Administration will allow emergency use of
Gilead's coronavirustreatment remdesivir.
- Remdesivir helped coronavirus patients recover 31% faster than those taking a placebo, the US National Institutes of
- The move allows for broader use of remdesivir. However an emergency use authorization is not regulatory approval. The FDA can apply a lower standard of evidence to allow emergency use.
- FDA is only allowing the use of remdesivir in relatively sick coronavirus patients who are hospitalized.
The US Food and Drug Administration is allowing emergency use of Gilead Sciences' new coronavirus treatment.
The regulatory action quickly followspositive trial results showing the drug, called remdesivir, helped coronavirus patients recover 31% faster than a group that got a placebo. Remdesivir has only been studied in hospitalized patients and is given as an IV infusion, so it's unlikely to become a broadly used treatment.An emergency use authorization is not the same as a typical approval. Emergency use is only allowed during public health emergencies, and treatments face a lower bar of evidence than used for FDA approval. There are no drugs that are specifically approved to treat COVID-19, the disease caused by the coronavirus.
The agency previously allowed the emergency use of chloroquine and hydroxychloroquine, the anti-malaria pills. It also stipulated these drugs were only to be used when a patient was hospitalized and could not enroll in a suitable clinical trial.Read more: Here's how 13 top drugmakers are sprinting to develop a coronavirus vaccine or treatment that can halt this pandemic
FDA is only allowing for the use of remdesivir in relatively sick coronavirus patients who are hospitalized. To be eligible for the drug, patients need to have severe symptoms of the disease, such as a need for oxygen or other help breathing. The US government will handle distribution of the drug.Read the original article on Business Insider
- Best broadband plans in India in 2021 – JioFiber, Airtel Xstream Fiber and ACT Fibernet
- IPL 2021: Royal Challengers Bangalore have beaten Sunrisers Hyderabad 7 out of 18 times they played each other
- Publicis Groupe consolidates Data Science, Programmatic and Media Tech with Zenith and Starcom, under a common leadership
- Here are the 7 Indians who will be a part of Cannes Lions Jury this year
- CBSE Class 10 board exams cancelled, Class 12 exams postponed as COVID-19 cases surge